ClinicalTrials.gg
CompletedNCT01229462Updated Sep 14, 2012Results posted

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

An interventional study of brimonidine tartrate/timolol fixed combination ophthalmic solution and brimonidine tartrate ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-14.

Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.

Enrollment
3rd of 21
238 · median 56
Started
2010
with 1 other
No phase
7 of 23
none open now
Registered
16th of 23
by date
Lead sponsor
5 of 23
Allergan

Among the 23 studies testing brimonidine in Glaucoma, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 with no phase, and was the 16th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing brimonidine in Glaucoma, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Open-angle glaucoma or ocular hypertension in at least one eye that is not responsive to topical beta blockers
  • No anticipated wearing of contact lenses during study

Exclusion criteria

Exclusion Criteria:

  • Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
  • Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months
  • Required regular use of other ocular medications except for occasional use of artificial tears
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
238 participants (actual)

Study arms

  • Other
    Combigan®

    One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.

    Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution · Other: fixed combination vehicle

  • Active comparator
    Alphagan® and Timolol Concurrent

    One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.

    Drug: brimonidine tartrate ophthalmic solution · Drug: timolol ophthalmic solution

Interventions

  • Drugbrimonidine tartrate/timolol fixed combination ophthalmic solution

    One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

    Also known as: Combigan®

  • One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

    Also known as: Alphagan®

  • One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.

  • Otherfixed combination vehicle

    Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4

    Intraocular pressure (IOP) was measured in the study eye at baseline and Week 4. IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).

    Time frame: Baseline, Week 4

07

Results

Posted Sep 14, 2012

Participant flow

Participant flow — Overall Study
MilestoneCombigan®Alphagan® and Timolol Concurrent
Started120118
Completed115109
Not completed59

Outcome measures

PrimaryChange From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4

Intraocular pressure (IOP) was measured in the study eye at baseline and Week 4. IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).

Time frame:
Baseline, Week 4
Reported as:
Mean · mm Hg
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4
mm HgCombigan®Alphagan® and Timolol Concurrent
Baseline25.07 ± 3.73724.53 ± 2.926
Change from baseline at Week 4-6.21 ± 3.550-5.70 ± 3.469

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combigan®—1/120 (0.8%)0/120 (0%)
Alphagan® and Timolol Concurrent—1/116 (0.9%)0/116 (0%)
Most frequent serious events
Most frequent serious events
EventCombigan®Alphagan® and Timolol Concurrent
VIth nerve paralysisNervous system disorders0/1201/116
Sudden hearing lossEar and labyrinth disorders1/1200/116

Baseline characteristics

Age Continuous
Age Continuous(Years)Combigan®Alphagan® and Timolol ConcurrentTotal
Mean46.2 ± 15.1848.2 ± 15.5747.2 ± 15.38
Sex: Female, Male
Sex: Female, Male(Participants)Combigan®Alphagan® and Timolol ConcurrentTotal
Female4855103
Male7263135
08

Study locations

1 site
  • Guangzhou, Guangdong, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2010
First posted
Oct 27, 2010
Start
Oct 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Sep 14, 2012
Last update
Sep 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01229462
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 27, 2010
Start date
Oct 2010
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Sep 14, 2012
Last update
Sep 14, 2012

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brimonidine · Timolol

Start the discussion